Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Thorn, the mouse models, biopsies etc. have all show us that the mechanism is working, so this means doxorubicin is getting deposited in the tumour and in sufficient concentrations to start killing tumour cells. The did provide us with the values in the science day. So this much we do know.
The independently defined therapeutic thresholds for the various mechanisms of action were listed in the science day slides as:
Doxorubicin Target Activity DOX IC50
DNA adduct formation 1 25nM
Free radical formation/cardiomyocyte apoptosis1 100nM
Topoisomerase Inhibition1 400nM
In vitro cytotoxicity2 30nM-3µM
Whereas, biopsies were in the range 79-2419nM.
This doesn't tell us what the values would be for straight dox, I agree.
It is true to say that straight dox is sucked up into the cells rapidly, with an initial half life of 5 minutes from tissue absorption alone. Once inside the cells they do their damage, both to the tumour cells, and to healthy tissue around the body. Essentially it is cells currently undergoing division are targeted by the dox (this is the most significant mechansim). Once inside the tissue there is a longer terminal half-life of 20-48 hours.
So it's probably safe to say on a like for like dose more straight dox will reach the tumour in the concentrations in which it is administered. However, you are also killing the person at the same time, which is less than ideal. You are also restricted to 3 weekly dosing due to the damage caused by the non-targeted distrubution of dox around all tissues.
Now considering the mechanism of action whereby only dividing tumour cells are actually destroyed by dox, and that only a subset of cells are dividing at any given time, the efficacy of administering straight dox (all other pharmacokinetic considerations aside) is limited by:
1. the number of dividing cells that can be targeted before dox is fully excreted
2. the growth of the tumour between the time the concentration of dox has dropped below an efficacious dose and the next dose can be administered
3. the time that has to be elapsed before a patient can receive another dose
Clearly if 2 is greater than 1, then sadly the tumour continues to grow (albeit more slowly) and the patient is very very sick from the doxorubicin alone.
Now compare the above to precision. Given that no mtd has been found yet, clinicians are free to adjust:
a. elapsed time between dosing
b. duration of a single dose ie. the rate it is administered
c. the maximum concentration of a single dose
all in the knowledge that healthy tissues are spared. Given we know there is already a therapeutic concentration found in biopsies, it is clear in my mind that if the dosing frequency and concentration are optimal, the clinicians will be able to ensure that dox can be administered to the tumour at such a rate that 1. (above) is greater than 2. and so the tumour begins to shrink.
This is all premised on the tumours being high fap and having
Hedge funds take out shorts when they expect a fall in the share price. GSA capital have not yet closed their short, and they only opened it in the low 50's as far as I can tell. Are they in the know? Should we be concerned about them? Did they really open a short with all the associated risk for just a few percent gain? Or, are they eyeing up that gap...
It's looking like the SP is struggling to get back above the support line that Zak Mir pointed out. Would it be sensible wyndrum, to take a bit off the table, just to hedge against the possibility of a 10-15% drop from here that you have suggested?
If another hedgie comes along and opens another huge short, they could push this down and cause those that bought around 43 to panic sell, dragging it down yet further. Before you know it, we'll be staring into the void of that gap.
Thorn?
So let's get this straight please wyndrum and aldebaran, is the share price going to rise from here? Does this mean we're well and truly out of the death spiral scenario, and Alan Smith is competent once again. I was under the impression that we need to dislodge him. How does this work - last week we needed to get him ousted with pitch forks?
Thorn - help me out here?
95% of all gaps are filled, plus remember the convertible bond death spiral that Thornogson kept going on about, that will definitely drag us down to 20p.
Isn't that right Thorn?
Over the coming months there's going to be massive dilution and it will provide downward pressure all the way down to 20p, maybe beyond?
The mechanisms employed, namely the conversion bond and raising exclusively with II’s at a huge discount (bar throwing a bone to long termers) supports that argument that they are reshaping the register. However, I don’t necessarily buy this given some of the “diamond handed” II’s that we saw participated. In addition, we’ve not seen a single tr1.
Nevertheless, this is still bargain territory and whatever the ultimate reasons for the raise, buying down here is still better than buying up at 160 by a factor of 4.